Een studie van metastasenvrije overleving met Saruparib vs placebo toegevoegd aan een standaard RT/ADT bij mannen met een hoog risico prostaatkanker met een BRCA-mutatie (EvoPAR-PR02)
13 oktober 2026 bijgewerkt door: AstraZeneca
Een gerandomiseerde, dubbelblinde, placebo-gecontroleerde, fase III-studie van adjuvante saruparib (AZD5305) bij patiënten met BrCAM gelokaliseerde risicovolle prostaatkanker die radiotherapie ontvangt met androgeendeprivatietherapie (EVOPAR-PROSTATE02).
The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen deprivation therapy (ADT) regimen by assessment of metastases-free survival in participants with high-risk and very high-risk localised/locally advanced prostate cancer with a breast cancer gene mutation (BRCAm).
Studie Overzicht
Toestand
Werving
Conditie
Gedetailleerde beschrijving
Approximately, 700 adult participants with localised/locally advanced prostate cancer will be randomized in a 1:1 ratio to receive saruparib or placebo with ADT (+ abiraterone) in one of the following two cohorts:
Cohort A: 400 adult participants with newly diagnosed high-risk and very high-risk (localised/locally advanced) prostate cancer who have received primary RT and are receiving continuous ADT, and participants with high-risk biochemical recurrence (BCR) [including prostate-specific antigen (PSA) persistence] following a radical prostatectomy who have received salvage RT are receiving continuous ADT.
Cohort B: 300 adult participants with newly diagnosed very high-risk (locally advanced) prostate cancer who have received primary RT and who are receiving continuous ADT and abiraterone.
All participants will be followed for survival until the end of the study. Independent data monitoring committee (DMC) composed of experts will be convened to confirm the safety and efficacy of Saruparib + ADT (+ abiraterone).
Studietype
Ingrijpend
Inschrijving (Geschat)
700
Fase
- Fase 3
Contacten en locaties
In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.
Studiecontact
- Naam: AstraZeneca Clinical Study Information Center
- Telefoonnummer: 1-877-240-9479
- E-mail: information.center@astrazeneca.com
Studie Locaties
-
-
-
CABA, Argentinië, C1113AAE
- Werving
- Research Site
-
CABA, Argentinië, 1426
- Werving
- Research Site
-
Ciudad de Buenos Aires, Argentinië, 1181
- Nog niet aan het werven
- Research Site
-
Ciudad de Buenos Aires, Argentinië, 1426
- Werving
- Research Site
-
Ciudad de Buenos Aires, Argentinië, C1419AHL
- Werving
- Research Site
-
Cuidad Autónoma de Buenos Aire, Argentinië, C1426ANZ
- Werving
- Research Site
-
Córdoba, Argentinië, 5000
- Nog niet aan het werven
- Research Site
-
Córdoba, Argentinië, X5008HHW
- Werving
- Research Site
-
La Plata, Argentinië, 1900
- Werving
- Research Site
-
Pergamino, Argentinië, B2700CPM
- Werving
- Research Site
-
Rosario, Argentinië, S2000KZE
- Werving
- Research Site
-
San Miguel de Tucumán, Argentinië, 4000
- Nog niet aan het werven
- Research Site
-
Viedma, Argentinië, R8500ACE
- Werving
- Research Site
-
-
-
-
-
Kingswood, Australië, 2747
- Ingetrokken
- Research Site
-
Murdoch, Australië, 6150
- Werving
- Research Site
-
Orange, Australië, 2800
- Werving
- Research Site
-
South Brisbane, Australië, 4101
- Werving
- Research Site
-
St Leonards, Australië, 2065
- Werving
- Research Site
-
Waratah, Australië, 2298
- Werving
- Research Site
-
Woolloongabba, Australië, 4102
- Werving
- Research Site
-
-
-
-
-
Brussels, België, 1200
- Werving
- Research Site
-
Brussels, België, 1070
- Ingetrokken
- Research Site
-
Ghent, België, 9000
- Ingetrokken
- Research Site
-
Jette, België, 1090
- Werving
- Research Site
-
Kortrijk, België, 8500
- Werving
- Research Site
-
Leuven, België, 3000
- Ingetrokken
- Research Site
-
Libramont-Chevigny, België, 6800
- Werving
- Research Site
-
Roeselare, België, 8800
- Werving
- Research Site
-
Wilrijk, België, 2610
- Werving
- Research Site
-
-
-
-
-
Barretos, Brazilië, 14784-400
- Nog niet aan het werven
- Research Site
-
Cachoeiro de Itapemirim, Brazilië, 29308-014
- Werving
- Research Site
-
Curitiba, Brazilië, 80810-050
- Werving
- Research Site
-
Curitiba, Brazilië
- Werving
- Research Site
-
Jaú, Brazilië, 17210-120
- Werving
- Research Site
-
Londrina, Brazilië, 86015-520
- Werving
- Research Site
-
Pelotas, Brazilië, 96020-080
- Werving
- Research Site
-
Porto Alegre, Brazilië, 91350200
- Werving
- Research Site
-
Porto Alegre, Brazilië, 90035-000
- Ingetrokken
- Research Site
-
Recife, Brazilië, 50070-460
- Nog niet aan het werven
- Research Site
-
Rio de Janeiro, Brazilië, 22775-001
- Werving
- Research Site
-
Rio de Janeiro, Brazilië, 22.250-905
- Werving
- Research Site
-
Salvador, Brazilië, 41950640
- Werving
- Research Site
-
São Paulo, Brazilië, 01246-000
- Werving
- Research Site
-
São Paulo, Brazilië, 01327-001
- Werving
- Research Site
-
-
-
-
-
Toronto, Canada, M4N 3M5
- Ingetrokken
- Research Site
-
-
Alberta
-
Calgary, Alberta, Canada, T2V 1P9
- Ingetrokken
- Research Site
-
-
British Columbia
-
Abbotsford British Columbia, British Columbia, Canada, V2S 0C2
- Ingetrokken
- Research Site
-
Vancouver, British Columbia, Canada, V5Z 4E6
- Ingetrokken
- Research Site
-
-
Ontario
-
Barrie, Ontario, Canada, L4M 6M2
- Ingetrokken
- Research Site
-
Brampton, Ontario, Canada, L6R 3J7
- Ingetrokken
- Research Site
-
London, Ontario, Canada, N6A 5A5
- Ingetrokken
- Research Site
-
Toronto, Ontario, Canada, M5G 2M9
- Ingetrokken
- Research Site
-
-
Quebec
-
Chicoutimi, Quebec, Canada, G7H 7K9
- Ingetrokken
- Research Site
-
Montreal, Quebec, Canada, H3T 1E2
- Ingetrokken
- Research Site
-
-
Saskatchewan
-
Saskatoon, Saskatchewan, Canada, S7N 4H4
- Ingetrokken
- Research Site
-
-
-
-
-
Concepción, Chili, 4070196
- Ingetrokken
- Research Site
-
La Serena, Chili, 1720430
- Ingetrokken
- Research Site
-
Temuco, Chili, 4781156
- Ingetrokken
- Research Site
-
-
-
-
-
Beijing, China, 100020
- Werving
- Research Site
-
Beijing, China, 100021
- Werving
- Research Site
-
Beijing, China, 100176
- Werving
- Research Site
-
Changchun, China, 130012
- Werving
- Research Site
-
Changsha, China, 410013
- Werving
- Research Site
-
Chongqing, China, 400016
- Werving
- Research Site
-
Guangzhou, China, 510280
- Werving
- Research Site
-
Guangzhou, China, 510080
- Werving
- Research Site
-
Guangzhou, China, 510060
- Werving
- Research Site
-
Guangzhou, China, 510180
- Werving
- Research Site
-
Hangzhou, China, 310022
- Werving
- Research Site
-
Hangzhou, China, 31000
- Nog niet aan het werven
- Research Site
-
Jinan, China, 250021
- Werving
- Research Site
-
Jinhua, China, 322100
- Werving
- Research Site
-
Lanzhou, China, 730030
- Ingetrokken
- Research Site
-
Nanchang, China, 330006
- Werving
- Research Site
-
Ningbo, China, 315010
- Werving
- Research Site
-
Shanghai, China, 200025
- Werving
- Research Site
-
Shanghai, China, 20032
- Ingetrokken
- Research Site
-
Shenyang, China, 110001
- Werving
- Research Site
-
Shenyang, China, 110042
- Ingetrokken
- Research Site
-
Sichuan, China, 610041
- Werving
- Research Site
-
Suining, China, 629018
- Werving
- Research Site
-
Tianjin, China, 300201
- Werving
- Research Site
-
Wuhan, China, 430022
- Werving
- Research Site
-
Wuhan, China, 430060
- Werving
- Research Site
-
Wuhu, China, 241000
- Werving
- Research Site
-
Xiamen, China, 361003
- Werving
- Research Site
-
Yangzhou, China, 225001
- Werving
- Research Site
-
Zhuhai, China, 519099
- Werving
- Research Site
-
-
-
-
-
Augsburg, Duitsland, 86156
- Werving
- Research Site
-
Berlin, Duitsland, 10117
- Werving
- Research Site
-
Braunschweig, Duitsland, 38126
- Werving
- Research Site
-
Cologne, Duitsland, 50937
- Werving
- Research Site
-
Dresden, Duitsland, 1307
- Werving
- Research Site
-
Duisburg, Duitsland, 47169
- Werving
- Research Site
-
Düsseldorf, Duitsland, 40226
- Werving
- Research Site
-
Essen, Duitsland, 45147
- Werving
- Research Site
-
Giessen, Duitsland, 35392
- Werving
- Research Site
-
Gronau, Duitsland, 48599
- Nog niet aan het werven
- Research Site
-
Göttingen, Duitsland, 37075
- Werving
- Research Site
-
Hamburg, Duitsland, 20246
- Werving
- Research Site
-
Herne, Duitsland, 44625
- Werving
- Research Site
-
Kiel, Duitsland, 24105
- Ingetrokken
- Research Site
-
Lübeck, Duitsland, 23538
- Werving
- Research Site
-
Marburg, Duitsland, 35043
- Werving
- Research Site
-
Münster, Duitsland, 48149
- Werving
- Research Site
-
Nuremberg, Duitsland, 90419
- Werving
- Research Site
-
Nürtingen, Duitsland, 72622
- Werving
- Research Site
-
Regensburg, Duitsland, 93053
- Werving
- Research Site
-
Schwerin, Duitsland, 19049
- Werving
- Research Site
-
Trier, Duitsland, 54292
- Werving
- Research Site
-
Ulm, Duitsland, 89081
- Werving
- Research Site
-
Würzburg, Duitsland, 97080
- Werving
- Research Site
-
-
-
-
-
Helsinki, Finland, 00290
- Werving
- Research Site
-
Helsinki, Finland, FI-00180
- Werving
- Research Site
-
Kuopio, Finland, 70210
- Werving
- Research Site
-
Oulu, Finland, 90029
- Nog niet aan het werven
- Research Site
-
Tampere, Finland, FI-33521
- Werving
- Research Site
-
Turku, Finland, 20520
- Werving
- Research Site
-
-
-
-
-
Angers, Frankrijk, 49100
- Werving
- Research Site
-
Bordeaux, Frankrijk, 33000
- Werving
- Research Site
-
Caen, Frankrijk, 14076
- Werving
- Research Site
-
Clermont-Ferrand, Frankrijk, 63011
- Werving
- Research Site
-
Le Mans, Frankrijk, 72000
- Werving
- Research Site
-
Marseille, Frankrijk, 13273
- Ingetrokken
- Research Site
-
Montpellier, Frankrijk, 34070
- Werving
- Research Site
-
Montpellier, Frankrijk, 34298
- Werving
- Research Site
-
Nice, Frankrijk, 06100
- Werving
- Research Site
-
Nîmes, Frankrijk, 30029
- Werving
- Research Site
-
Paris, Frankrijk, 75020
- Werving
- Research Site
-
Paris, Frankrijk, 75970
- Werving
- Research Site
-
Paris, Frankrijk, 75674
- Werving
- Research Site
-
Pierre-Bénite, Frankrijk, 69310
- Werving
- Research Site
-
Rennes, Frankrijk, 35000
- Ingetrokken
- Research Site
-
Saint-Herblain, Frankrijk, 44805
- Werving
- Research Site
-
Saint-Priest-en-Jarez, Frankrijk, 42270
- Werving
- Research Site
-
Strasbourg, Frankrijk, 67200
- Werving
- Research Site
-
Suresnes, Frankrijk, 92151
- Werving
- Research Site
-
Tours, Frankrijk, 37044
- Werving
- Research Site
-
Vandœuvre-lès-Nancy, Frankrijk, 54511
- Werving
- Research Site
-
Villejuif, Frankrijk, 94805
- Werving
- Research Site
-
-
-
-
-
Budapest, Hongarije, 1122
- Werving
- Research Site
-
Budapest, Hongarije, 1082
- Werving
- Research Site
-
Budapest, Hongarije, H-1145
- Ingetrokken
- Research Site
-
Debrecen, Hongarije, 4032
- Werving
- Research Site
-
Gyula, Hongarije, 5700
- Werving
- Research Site
-
Győr, Hongarije, 9024
- Werving
- Research Site
-
Zalaegerszeg, Hongarije, 8900
- Werving
- Research Site
-
-
-
-
-
Ansārinagar, Indië, 110 029
- Werving
- Research Site
-
Babgalore, Indië, 560069
- Werving
- Research Site
-
Calicut, Indië, 673601
- Ingetrokken
- Research Site
-
Delhi, Indië, 110085
- Ingetrokken
- Research Site
-
Hyderabad, Indië, 500019
- Werving
- Research Site
-
Kannur, Indië, 670103
- Werving
- Research Site
-
Kanpur, Indië, 208005
- Werving
- Research Site
-
Mumbai, Indië, 400012
- Werving
- Research Site
-
Nagpur, Indië, 440001
- Werving
- Research Site
-
Varanasi, Indië, 221005
- Werving
- Research Site
-
-
-
-
-
Afula, Israël, 18101
- Werving
- Research Site
-
Beersheba, Israël, 8410101
- Werving
- Research Site
-
Hadera, Israël, 38100
- Nog niet aan het werven
- Research Site
-
Haifa, Israël, 31096
- Werving
- Research Site
-
Jerusalem, Israël, 91031
- Werving
- Research Site
-
Jerusalem, Israël, 9112001
- Werving
- Research Site
-
Kfar Saba, Israël, 4428164
- Werving
- Research Site
-
Nahariya, Israël, 22100
- Nog niet aan het werven
- Research Site
-
Petah Tikva, Israël, 49100
- Werving
- Research Site
-
Ramat Gan, Israël, 52621
- Werving
- Research Site
-
Tel Aviv, Israël, 6423906
- Werving
- Research Site
-
-
-
-
-
Arezzo, Italië, 52100
- Werving
- Research Site
-
Bari, Italië, 70124
- Werving
- Research Site
-
Bergamo, Italië, 24127
- Werving
- Research Site
-
Bergamo, Italië, 24125
- Werving
- Research Site
-
Chieti, Italië, 66100
- Nog niet aan het werven
- Research Site
-
Genoa, Italië, 16132
- Werving
- Research Site
-
Milan, Italië, 20132
- Werving
- Research Site
-
Milan, Italië, 20141
- Werving
- Research Site
-
Milan, Italië, 20133
- Werving
- Research Site
-
Naples, Italië, 80131
- Werving
- Research Site
-
Palermo, Italië, 90127
- Werving
- Research Site
-
Pisa, Italië, 56126
- Werving
- Research Site
-
Roma, Italië, 00168
- Werving
- Research Site
-
Roma, Italië, 00144
- Werving
- Research Site
-
Rozzano, Italië, 20089
- Werving
- Research Site
-
Torino, Italië, 10126
- Werving
- Research Site
-
Varese, Italië, 21100
- Werving
- Research Site
-
Verona, Italië, 37134
- Werving
- Research Site
-
-
-
-
-
Bunkyō City, Japan, 113-8431
- Werving
- Research Site
-
Fukuoka, Japan, 812-8582
- Werving
- Research Site
-
Kamakura-shi, Japan, 247-8533
- Werving
- Research Site
-
Kawagoe-shi, Japan, 350-8550
- Werving
- Research Site
-
Kawasaki-shi, Japan, 216-8511
- Werving
- Research Site
-
Kisarazu-shi, Japan, 292-8535
- Werving
- Research Site
-
Kumamoto, Japan, 860-8556
- Werving
- Research Site
-
Kyoto, Japan, 606-8507
- Nog niet aan het werven
- Research Site
-
Maebashi, Japan, 371-8511
- Werving
- Research Site
-
Miyazaki, Japan, 889-1692
- Werving
- Research Site
-
Sagamihara-shi, Japan, 252-0375
- Werving
- Research Site
-
Shimotsuke-shi, Japan, 329-0498
- Werving
- Research Site
-
Yokohama, Japan, 241-8515
- Werving
- Research Site
-
Yokohama, Japan, 232-0024
- Werving
- Research Site
-
Ōta-ku, Japan, 373-8550
- Werving
- Research Site
-
-
-
-
-
Batu Caves, Maleisië, 68100
- Ingetrokken
- Research Site
-
Kuala Lumpur, Maleisië, 59100
- Ingetrokken
- Research Site
-
Kuala Selangor, Maleisië, 62250
- Ingetrokken
- Research Site
-
Pulau Pinang, Maleisië, 10450
- Ingetrokken
- Research Site
-
-
-
-
-
Hilversum, Nederland, 1213 XZ
- Werving
- Research Site
-
Hoofddorp, Nederland, 2134 TM
- Ingetrokken
- Research Site
-
Maastricht, Nederland, 6202 AZ
- Werving
- Research Site
-
Nijmegen, Nederland, 6532 SZ
- Werving
- Research Site
-
Roosendaal, Nederland, 4708 AE
- Werving
- Research Site
-
-
-
-
-
Graz, Oostenrijk, 8036
- Werving
- Research Site
-
Innsbruck, Oostenrijk, 6020
- Werving
- Research Site
-
Linz, Oostenrijk, 4020
- Werving
- Research Site
-
Vienna, Oostenrijk, 1090
- Nog niet aan het werven
- Research Site
-
Vienna, Oostenrijk, 1020
- Werving
- Research Site
-
-
-
-
-
Lima, Peru, 15036
- Ingetrokken
- Research Site
-
Lima, Peru, LIMA 29
- Ingetrokken
- Research Site
-
Lima, Peru, Lima 34
- Ingetrokken
- Research Site
-
Trujillo, Peru, 13008
- Ingetrokken
- Research Site
-
-
-
-
-
Gdynia, Polen, 81-519
- Werving
- Research Site
-
Gliwice, Polen, 44-101
- Werving
- Research Site
-
Koszalin, Polen, 75-581
- Werving
- Research Site
-
Krakow, Polen, 30-727
- Werving
- Research Site
-
Piotrkow Trybunalski, Polen, 97-300
- Werving
- Research Site
-
Poznan, Polen, 61-731
- Werving
- Research Site
-
Rzeszów, Polen, 35-001
- Werving
- Research Site
-
Warsaw, Polen, 04-073
- Werving
- Research Site
-
-
-
-
-
Barcelona, Spanje, 08041
- Werving
- Research Site
-
Barcelona, Spanje, 8035
- Werving
- Research Site
-
Girona, Spanje, 17007
- Werving
- Research Site
-
Madrid, Spanje, 28040
- Werving
- Research Site
-
Madrid, Spanje, 28041
- Werving
- Research Site
-
Madrid, Spanje, 28046
- Werving
- Research Site
-
Majadahonda, Spanje, 28222
- Werving
- Research Site
-
Málaga, Spanje, 29010
- Werving
- Research Site
-
Málaga, Spanje, 29009
- Werving
- Research Site
-
Oviedo, Spanje, 33011
- Werving
- Research Site
-
Sabadell, Spanje, 08208
- Werving
- Research Site
-
Santander, Spanje, 39008
- Werving
- Research Site
-
Valencia, Spanje, 46014
- Werving
- Research Site
-
Valencia, Spanje, 46009
- Werving
- Research Site
-
-
-
-
-
Kaohsiung City, Taiwan, 83301
- Werving
- Research Site
-
Taichung, Taiwan, 40705
- Werving
- Research Site
-
Taichung, Taiwan, 43503
- Werving
- Research Site
-
Tainan, Taiwan, 704
- Werving
- Research Site
-
Taipei, Taiwan, 112
- Werving
- Research Site
-
Taipei, Taiwan, 110
- Werving
- Research Site
-
Taipei, Taiwan, 10055
- Werving
- Research Site
-
Taoyuan, Taiwan, 333
- Werving
- Research Site
-
-
-
-
-
Bangkok, Thailand, 10210
- Werving
- Research Site
-
Bangkok, Thailand, 10400
- Werving
- Research Site
-
Bangkok, Thailand, 10700
- Werving
- Research Site
-
Khon Kaen, Thailand, 40002
- Werving
- Research Site
-
Muang, Thailand, 50200
- Werving
- Research Site
-
Pathum Thani, Thailand, 12120
- Werving
- Research Site
-
Songkhla, Thailand, 90110
- Werving
- Research Site
-
-
-
-
-
Ankara, Turkije (Türkiye), 06800
- Werving
- Research Site
-
Ankara, Turkije (Türkiye), 06620
- Werving
- Research Site
-
Ankara, Turkije (Türkiye), 06010
- Werving
- Research Site
-
Ankara, Turkije (Türkiye), 06520
- Werving
- Research Site
-
Cordaleo, Turkije (Türkiye), 35575
- Werving
- Research Site
-
Diyarbakır, Turkije (Türkiye), 21280
- Werving
- Research Site
-
Istanbul, Turkije (Türkiye), 34722
- Werving
- Research Site
-
Istanbul, Turkije (Türkiye), 34098
- Werving
- Research Site
-
Istanbul, Turkije (Türkiye), 34010
- Werving
- Research Site
-
Izmir, Turkije (Türkiye), 35040
- Werving
- Research Site
-
Sakarya, Turkije (Türkiye), 54290
- Werving
- Research Site
-
Seyhan, Turkije (Türkiye), 01130
- Ingetrokken
- Research Site
-
Şahinbey, Turkije (Türkiye), 27310
- Werving
- Research Site
-
-
-
-
-
Aberdeen, Verenigd Koninkrijk, AB25 2ZN
- Werving
- Research Site
-
Bristol, Verenigd Koninkrijk, BS2 8ED
- Werving
- Research Site
-
Cambridge, Verenigd Koninkrijk, CB2 0QQ
- Werving
- Research Site
-
Edinburgh, Verenigd Koninkrijk, EH4 2XU
- Werving
- Research Site
-
Exeter, Verenigd Koninkrijk, EX2 5DW
- Werving
- Research Site
-
Glasgow, Verenigd Koninkrijk, G12 0YN
- Werving
- Research Site
-
Greater London, Verenigd Koninkrijk, SW3 6JJ
- Werving
- Research Site
-
Guildford, Verenigd Koninkrijk, GU2 7XX
- Werving
- Research Site
-
London, Verenigd Koninkrijk, NW3 2QG
- Werving
- Research Site
-
London, Verenigd Koninkrijk, WC1N 3BG
- Werving
- Research Site
-
London, Verenigd Koninkrijk, EC1M6BQ
- Ingetrokken
- Research Site
-
Manchester, Verenigd Koninkrijk, M20 4BX
- Werving
- Research Site
-
Newcastle, Verenigd Koninkrijk, NE7 7DN
- Ingetrokken
- Research Site
-
Plymouth, Verenigd Koninkrijk, PL6 8DH
- Werving
- Research Site
-
Preston, Verenigd Koninkrijk, PR2 9HT
- Ingetrokken
- Research Site
-
Romford, Verenigd Koninkrijk, RM7 0AG
- Werving
- Research Site
-
-
-
-
Arizona
-
Phoenix, Arizona, Verenigde Staten, 85054
- Werving
- Research Site
-
Tucson, Arizona, Verenigde Staten, 85741
- Ingetrokken
- Research Site
-
-
California
-
La Jolla, California, Verenigde Staten, 92037
- Werving
- Research Site
-
La Jolla, California, Verenigde Staten, 92093
- Werving
- Research Site
-
Los Angeles, California, Verenigde Staten, 90048
- Werving
- Research Site
-
San Diego, California, Verenigde Staten, 92123
- Werving
- Research Site
-
San Luis Obispo, California, Verenigde Staten, 93401
- Werving
- Research Site
-
-
Colorado
-
Lakewood, Colorado, Verenigde Staten, 80215
- Werving
- Research Site
-
-
Florida
-
Hialeah, Florida, Verenigde Staten, 33016
- Werving
- Research Site
-
Jacksonville, Florida, Verenigde Staten, 32224
- Werving
- Research Site
-
Tallahassee, Florida, Verenigde Staten, 32308
- Ingetrokken
- Research Site
-
Tampa, Florida, Verenigde Staten, 33612
- Werving
- Research Site
-
-
Georgia
-
Newnan, Georgia, Verenigde Staten, 30265
- Werving
- Research Site
-
-
Illinois
-
Chicago, Illinois, Verenigde Staten, 60611
- Werving
- Research Site
-
Chicago Ridge, Illinois, Verenigde Staten, 60415
- Werving
- Research Site
-
Lake Barrington, Illinois, Verenigde Staten, 60010
- Ingetrokken
- Research Site
-
-
Indiana
-
Greenwood, Indiana, Verenigde Staten, 46143
- Werving
- Research Site
-
Jeffersonville, Indiana, Verenigde Staten, 47130
- Ingetrokken
- Research Site
-
-
Maryland
-
Bethesda, Maryland, Verenigde Staten, 20817
- Ingetrokken
- Research Site
-
Towson, Maryland, Verenigde Staten, 21204
- Werving
- Research Site
-
-
Massachusetts
-
Plymouth, Massachusetts, Verenigde Staten, 02360
- Werving
- Research Site
-
-
Minnesota
-
Rochester, Minnesota, Verenigde Staten, 55905
- Werving
- Research Site
-
-
New Jersey
-
Hackensack, New Jersey, Verenigde Staten, 07601
- Werving
- Research Site
-
Voorhees Township, New Jersey, Verenigde Staten, 08043
- Werving
- Research Site
-
-
New York
-
Albany, New York, Verenigde Staten, 12206
- Ingetrokken
- Research Site
-
New York, New York, Verenigde Staten, 10065
- Werving
- Research Site
-
Syracuse, New York, Verenigde Staten, 13210
- Werving
- Research Site
-
-
Ohio
-
Columbus, Ohio, Verenigde Staten, 43230
- Werving
- Research Site
-
-
Oregon
-
Springfield, Oregon, Verenigde Staten, 97477
- Werving
- Research Site
-
-
Pennsylvania
-
Hershey, Pennsylvania, Verenigde Staten, 17033
- Werving
- Research Site
-
Lancaster, Pennsylvania, Verenigde Staten, 17601
- Werving
- Research Site
-
Pittsburgh, Pennsylvania, Verenigde Staten, 15212
- Werving
- Research Site
-
-
Rhode Island
-
Providence, Rhode Island, Verenigde Staten, 02903
- Werving
- Research Site
-
-
South Carolina
-
Myrtle Beach, South Carolina, Verenigde Staten, 29572
- Werving
- Research Site
-
-
Tennessee
-
Nashville, Tennessee, Verenigde Staten, 37209
- Werving
- Research Site
-
-
Texas
-
Austin, Texas, Verenigde Staten, 78745
- Werving
- Research Site
-
Austin, Texas, Verenigde Staten, 78705
- Werving
- Research Site
-
Houston, Texas, Verenigde Staten, 77074
- Werving
- Research Site
-
San Antonio, Texas, Verenigde Staten, 78229
- Werving
- Research Site
-
Spring, Texas, Verenigde Staten, 77380
- Werving
- Research Site
-
-
Utah
-
Salt Lake City, Utah, Verenigde Staten, 84112
- Ingetrokken
- Research Site
-
-
Virginia
-
Norfolk, Virginia, Verenigde Staten, 23502
- Werving
- Research Site
-
Roanoke, Virginia, Verenigde Staten, 24014
- Werving
- Research Site
-
Virginia Beach, Virginia, Verenigde Staten, 23462
- Werving
- Research Site
-
-
Washington
-
Seattle, Washington, Verenigde Staten, 98109
- Ingetrokken
- Research Site
-
-
-
-
-
Busan, Zuid -Korea, 49241
- Werving
- Research Site
-
Daegu, Zuid -Korea, 41404
- Werving
- Research Site
-
Goyang-si, Zuid -Korea, 10408
- Werving
- Research Site
-
Seongnam-si, Zuid -Korea, 13620
- Ingetrokken
- Research Site
-
Seoul, Zuid -Korea, 03080
- Werving
- Research Site
-
Seoul, Zuid -Korea, 06351
- Werving
- Research Site
-
Seoul, Zuid -Korea, 5505
- Werving
- Research Site
-
Seoul, Zuid -Korea, 06591
- Werving
- Research Site
-
Seoul, Zuid -Korea, 3722
- Werving
- Research Site
-
Seoul, Zuid -Korea, 06273
- Werving
- Research Site
-
-
-
-
-
Gothenburg, Zweden, 413 45
- Werving
- Research Site
-
Malmö, Zweden, 205 02
- Werving
- Research Site
-
Stockholm, Zweden, 141 86
- Werving
- Research Site
-
Stockholm, Zweden, 112 81
- Ingetrokken
- Research Site
-
Umeå, Zweden, 901 85
- Werving
- Research Site
-
Uppsala, Zweden, 75185
- Werving
- Research Site
-
-
Deelname Criteria
Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
18 jaar en ouder (Volwassen, Oudere volwassene)
Accepteert gezonde vrijwilligers
Nee
Geslachten die in aanmerking komen voor studie
Mannelijk
Beschrijving
Inclusion Criteria:
- Male participants with a histologically documented diagnosis of prostate adenocarcinoma.
- Newly diagnosed high-risk and very high-risk (localised/locally advanced) prostate cancer or a high-risk biochemical recurrence (BCR) following radical prostatectomy.
- Provision of a formalin fixed and paraffin embedded (FFPE) tumour tissue sample.
- Confirmed BRCA1 or BRCA2 mutation status by central tumour tissue is required for enrolment.
- Participants required to have a computed tomography (CT) or magnetic resonance imaging (MRI) and a bone scan following the completion of their planned RT. This screening scan must confirm no evidence of disease or evidence of disease confined to the pelvis (M0).
- Participants required to have a prostate-specific membrane antigen-positron emission tomography (PSMA-PET) following the completion of their planned RT. This screening scan must confirm no evidence of disease or evidence of disease confined to the pelvis (M0).
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 with no deterioration over the 2 weeks prior to randomization.
- Minimum life expectancy of 12 months.
- Adequate organ and bone marrow function as described in study protocol.
- All participants will have received either primary or salvage RT. Participants must be eligible for randomisation within 10 months of initial diagnosis (de novo or BCR). Radiotherapy administered to the prostate (± pelvis) either in the primary or salvage setting must be delivered with curative intent. Use of metastases-directed therapy, as part of the RT radiation plan, is permitted as localised RT treatment for a metastatic lesion(s) outside the pelvis.
- All participants will have received a planned regimen of ADT with a gonadotropin releasing hormone (GnRH) analogue.
- Participants must not father children or donate sperm from signing informed consent form (ICF), during the study intervention and for 6 months after the last dose of study intervention.
- Participants must use a condom (with spermicide - where permitted) from signing ICF, during study intervention, and for 6 months after the last dose of study drug, with all sexual partners.
Exclusion Criteria:
- Participants with a history of myelodysplastic syndrome (MDS)/ acute myeloid leukemia (AML) or with features suggestive of MDS/AML.
- Participants with any known predisposition to bleeding [e.g., active peptic ulceration, recent (within 6 months) hemorrhagic stroke, proliferative diabetic retinopathy].
- Any history of persisting (> 2 weeks) severe cytopenia due to any cause.
- Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of saruparib and/or abiraterone.
- History of another primary malignancy, with exceptions.
- Persistent toxicities [Common Terminology Criteria for Adverse Events (CTCAE) Grade ≥ 2] caused by previous anticancer therapy.
- Cardiac criteria, including history of arrhythmia and cardiovascular disease.
- Evidence of active and uncontrolled hepatitis B and/or hepatitis C.
- Evidence of active and uncontrolled human immunodeficiency virus (HIV) infection.
- Active tuberculosis infection.
- Any prior chemotherapy (i.e., docetaxel) or immunotherapy; any prior treatment with a poly (ADP-ribose) polymerase (PARP) inhibitor.
- Prior treatment within 14 days with blood product support or growth factor support.
- Concomitant use of strong inducers and inhibitors of CYP3A4 (applies to saruparib and abiraterone) or herbal supplements within 21 days or at least 5 half-lives (whichever is longer), of randomization.
- Concomitant use of drugs that are known to prolong QT and have a known risk of Torsades de Pointes (TdP).
- Participants with a known hypersensitivity to saruparib or any excipients of these products.
Studie plan
Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verviervoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Cohort A: Saruparib (AZD5305) + Physician's Choice ADT
Participants will receive saruparib along with ADT. |
Saruparib will be administered orally.
Andere namen:
Standard of care ADT will be administered. |
|
Placebo-vergelijker: Cohort A: Placebo + Physician's Choice ADT
Participants will receive matching placebo to saruparib along with ADT. |
Standard of care ADT will be administered. Matching placebo to saruparib will be administered orally. |
|
Experimenteel: Cohort B: Saruparib (AZD5305) + Physician's Choice ADT + Abiraterone (and prednisone/prednisolone)
Participants will receive saruparib, abiraterone and prednisolone/prednisone along with ADT. |
Saruparib will be administered orally.
Andere namen:
Standard of care ADT will be administered. Abiraterone will be administered orally in combination with prednisone/prednisolone. |
|
Placebo-vergelijker: Cohort B: Placebo + Physician's Choice ADT + Abiraterone (and prednisone/prednisolone)
Participants will receive matching placebo to saruparib, abiraterone and prednisolone/prednisone along with ADT. |
Standard of care ADT will be administered. Matching placebo to saruparib will be administered orally. Abiraterone will be administered orally in combination with prednisone/prednisolone. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Metastasis-free survival (MFS)
Tijdsspanne: Up to approximately 93 months
|
MFS is defined as the time from randomisation until the date of first appearance of distant metastases, confirmed by standard clinical imaging [computed tomography (CT)/ magnetic resonance imaging (MRI) and bone scan, or prostate-specific membrane antigen-positron emission tomography (PSMA-PET)], as assessed by blinded independent central review (BICR) or death due to any cause. |
Up to approximately 93 months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Overall Survival (OS)
Tijdsspanne: Up to approximately 11 years
|
OS is defined as the time from randomisation until the date of death due to any cause. |
Up to approximately 11 years
|
|
MFS (CT/MRI and bone scan)
Tijdsspanne: Up to approximately 93 months
|
MFS is defined as the time from randomisation until the date of distant metastases, confirmed by conventional imaging (CT/MRI and bone scan), or death due to any cause. |
Up to approximately 93 months
|
|
MFS (PSMA-PET)
Tijdsspanne: Up to approximately 93 months
|
MFS is defined as the time from randomisation until the date of distant metastases, confirmed by PSMA-PET imaging or death due to any cause. |
Up to approximately 93 months
|
|
MFS (standard clinical imaging)
Tijdsspanne: Up to approximately 93 months
|
MFS is defined as the time from randomisation until the date of distant metastases, confirmed by standard clinical imaging (CT/MRI and bone scan or PSMA-PET), histology, or death due to any cause. |
Up to approximately 93 months
|
|
Time from randomisation to Progression Free Survival 2 (PFS2)
Tijdsspanne: Up to approximately 93 months
|
Time from randomisation to PFS2 is defined as the time from randomisation to the earliest of progression [defined as radiographic progression, clinical progression, or prostate-specific antigen (PSA) progression] after initiation of first subsequent systemic treatment following the initial investigator-assessed progression or death. The date of second progression will be investigator assessed according to local standard clinical practice. |
Up to approximately 93 months
|
|
Time to biochemical recurrence
Tijdsspanne: Up to approximately 93 months
|
Time to biochemical recurrence is defined as the time from randomisation to biochemical recurrence per Phoenix criteria. |
Up to approximately 93 months
|
|
Prostate cancer-specific survival (PCSS)
Tijdsspanne: Up to approximately 11 years
|
PCSS is defined as the time from randomisation until the date of death due to the underlying prostate cancer. |
Up to approximately 11 years
|
|
Time to deterioration in urinary symptoms (TTDUS)
Tijdsspanne: Up to approximately 93 months
|
TTDUS is defined as the time from randomisation to deterioration in EORTC-QLQ-PR25 (US) subscale scores. |
Up to approximately 93 months
|
|
Time to deterioration in physical function (TTDPF)
Tijdsspanne: Up to approximately 93 months
|
TTDPF is defined as the time from randomisation to deterioration in EORTC-QLQ-C30 Physical Function subscale scores. |
Up to approximately 93 months
|
|
Plasma concentrations of saruparib
Tijdsspanne: Day 1 of Cycle 1, Cycle 3 and Cycle 6 (each cycle is of 28 days)
|
To assess the PK of saruparib in plasma either with or without abiraterone and explore the relationship between the PK concentration/parameters and selected endpoints (which may include pharmacodynamic parameters, efficacy, and/or safety). |
Day 1 of Cycle 1, Cycle 3 and Cycle 6 (each cycle is of 28 days)
|
|
Area under the curve (AUC)
Tijdsspanne: Day 1 of Cycle 1, Cycle 3 and Cycle 6 (each cycle is of 28 days)
|
To assess the PK of saruparib in plasma either with or without abiraterone and explore the relationship between the PK concentration/parameters and selected endpoints (which may include pharmacodynamic parameters, efficacy, and/or safety). |
Day 1 of Cycle 1, Cycle 3 and Cycle 6 (each cycle is of 28 days)
|
|
Maximum observed concentration (Cmax)
Tijdsspanne: Day 1 of Cycle 1, Cycle 3 and Cycle 6 (each cycle is of 28 days)
|
To assess the PK of saruparib in plasma either with or without abiraterone and explore the relationship between the PK concentration/parameters and selected endpoints (which may include pharmacodynamic parameters, efficacy, and/or safety). |
Day 1 of Cycle 1, Cycle 3 and Cycle 6 (each cycle is of 28 days)
|
|
Time to Cmax (Tmax)
Tijdsspanne: Day 1 of Cycle 1, Cycle 3 and Cycle 6 (each cycle is of 28 days)
|
To assess the PK of saruparib in plasma either with or without abiraterone and explore the relationship between the PK concentration/parameters and selected endpoints (which may include pharmacodynamic parameters, efficacy, and/or safety). |
Day 1 of Cycle 1, Cycle 3 and Cycle 6 (each cycle is of 28 days)
|
|
Number of participants with adverse events (AEs)
Tijdsspanne: Up to approximately 11 years
|
To assess the safety and tolerability of saruparib administered in combination with ADT alone (Cohort A) and in combination with ADT + abiraterone (Cohort B). |
Up to approximately 11 years
|
Medewerkers en onderzoekers
Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.
Sponsor
Medewerkers
Studie record data
Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.
Bestudeer belangrijke data
Studie start (Werkelijk)
6 augustus 2025
Primaire voltooiing (Geschat)
31 maart 2033
Studie voltooiing (Geschat)
30 april 2036
Studieregistratiedata
Eerst ingediend
30 april 2025
Eerst ingediend dat voldeed aan de QC-criteria
30 april 2025
Eerst geplaatst (Werkelijk)
1 mei 2025
Updates van studierecords
Laatste update geplaatst (Werkelijk)
14 oktober 2026
Laatste update ingediend die voldeed aan QC-criteria
13 oktober 2026
Laatst geverifieerd
1 oktober 2026
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Urogenitale ziekten
- Genitale ziekten
- Genitale neoplasmata, mannelijk
- Urogenitale neoplasmata
- Neoplasmata per site
- Neoplasmata
- Genitale ziekten, man
- Prostaat Ziekten
- Mannelijke urogenitale ziekten
- Prostaatneoplasmata
- Fysiologische effecten van medicijnen
- Hormonen, hormoonvervangers en hormoonantagonisten
- Hormoonantagonisten
- Farmacologische acties
- Chemische acties en gebruik
- Polycyclische verbindingen
- Zwangerschap
- Zwangere
- Steroïden
- Verbindingen met gefuseerde ring
- Zwangerschap
- Zwangerschap
- Prednison
- Prednisolon
- Androgeenantagonisten
- abirateron
- AZD5305
Andere studie-ID-nummers
- D9727C00001
- 2024-513586-39 (Andere identificatie: EU CT Number)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
JA
Beschrijving IPD-plan
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment:
https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD-tijdsbestek voor delen
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD-toegangscriteria voor delen
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
IPD delen Ondersteunend informatietype
- LEERPROTOCOOL
- SAP
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Ja
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Nee
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .